Physician profile
Deepa Ujwal
NPI 1952686537
$668.25
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $38.83.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $226.08 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $109.13 | 2019 | |
| Lundbeck LLC | $64.36 | 2019 | |
| Neurocrine Biosciences, INC. | $61.05 | 2019 | |
| Alkermes, INC. | $50.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $37.73 | 2019 | |
| Abiomed | $32.93 | 2019 | |
| Allergan, INC. | $22.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.96 | 2020 | |
| Vanda Pharmaceuticals INC. | $15.28 | 2019 | |
| Indivior INC. | $13.90 | 2019 | |
| Shire North American Group INC | $12.84 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Ujwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.